CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL TRIAL OF SYS6063 FOR THE TREATMENT OF RELAPSED, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase I clinical trial of SYS6063 (the "**Product**") developed by the Group for the treatment of relapsed, refractory systemic lupus erythematosus ("**SLE**") has been officially initiated at the first centre in China.

The Product is currently the world's first chimeric antigen receptor T-cell ("**CAR-T**") product based on LNP-mRNA transfection targeting CD19/BCMA to have obtained approval to conduct clinical trials in SLE. The Product utilises lipid nanoparticles ("**LNP**") to transfect T cells with CAR mRNA expressing both CD19 and BCMA, enabling the T cells to express two complete CAR proteins simultaneously, thereby effectively eliminating CD19- and BCMA-positive cells that secrete autoreactive antibodies. The Product is expected to offer a novel, safe and effective potential treatment option for SLE patients. Currently, no CAR-T therapy has been approved worldwide for the treatment of SLE.

Compared with conventional CAR-T products, the Product offers advantages including high cell viability, high CAR-positive rate, the absence of tumourigenic risk associated with genomic integration, and a low incidence of adverse reactions such as cytokine release syndrome ("**CRS**"). Preclinical studies showed that the Product effectively eliminated CD19- and BCMA-positive tumour cells, and demonstrated a favourable safety profile. From a cost perspective, the adoption of LNP for T-cell transfection avoids the high costs associated with lentiviral vectors, thereby substantially alleviating the economic burden on patients.

Previously, the Group obtained the Notice of Approval for Clinical Trial of Drug from the National Medical Products Administration of the People's Republic of China in June 2026, and initiated the Phase I clinical trial of the Product for the treatment of SLE following the approval. This Phase I clinical trial is a single-arm, open-label, two-stage (dose escalation and dose expansion), multi-centre clinical study conducted in patients with relapsed, refractory SLE, aiming to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of the Product in SLE patients. Currently, patient recruitment and screening are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 11 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.